BR112022015015A2 - Usos terapêuticos de tirzepatida - Google Patents

Usos terapêuticos de tirzepatida

Info

Publication number
BR112022015015A2
BR112022015015A2 BR112022015015A BR112022015015A BR112022015015A2 BR 112022015015 A2 BR112022015015 A2 BR 112022015015A2 BR 112022015015 A BR112022015015 A BR 112022015015A BR 112022015015 A BR112022015015 A BR 112022015015A BR 112022015015 A2 BR112022015015 A2 BR 112022015015A2
Authority
BR
Brazil
Prior art keywords
tirzepatide
heart failure
therapeutic uses
treating
preventing
Prior art date
Application number
BR112022015015A
Other languages
English (en)
Inventor
Paul Coghlan Matthew
Haupt Axel
Murakami Masahiro
Scott Riesmeyer Jeffrey
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR112022015015A2 publication Critical patent/BR112022015015A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)

Abstract

USOS TERAPÊUTICOS DE TIRZEPATIDA. A presente invenção refere-se a métodos para tratar, prevenir ou retardar transtornos relacionados à cognição, tais como declínio cognitivo, comprometimento cognitivo ou demência. A presente invenção refere-se também a um método para tratar, prevenir ou retardar insuficiência cardíaca, tal como insuficiência cardíaca com fração de ejeção preservada (HFpEF) ou insuficiência cardíaca com fração de ejeção reduzida (HFrEF).
BR112022015015A 2020-01-30 2021-01-22 Usos terapêuticos de tirzepatida BR112022015015A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062967867P 2020-01-30 2020-01-30
PCT/US2021/014535 WO2021154593A1 (en) 2020-01-30 2021-01-22 Therapeutic uses of tirzepatide

Publications (1)

Publication Number Publication Date
BR112022015015A2 true BR112022015015A2 (pt) 2022-09-20

Family

ID=77078332

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022015015A BR112022015015A2 (pt) 2020-01-30 2021-01-22 Usos terapêuticos de tirzepatida

Country Status (12)

Country Link
US (1) US20230355719A1 (pt)
EP (1) EP4096703A4 (pt)
JP (2) JP2023513076A (pt)
KR (1) KR20220132607A (pt)
CN (1) CN115279395A (pt)
AU (1) AU2021213064A1 (pt)
BR (1) BR112022015015A2 (pt)
CA (1) CA3166567A1 (pt)
IL (1) IL295181A (pt)
MX (1) MX2022009384A (pt)
TW (2) TW202140058A (pt)
WO (1) WO2021154593A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023008330A (es) 2021-01-20 2024-01-18 Viking Therapeutics Inc Agonistas del receptor dual gip/glp-1 de molécula pequeña, composiciones farmacéuticas y preparación de las mismas para usarse en el tratamiento de trastornos metabólicos y hepáticos.
CN116867505A (zh) * 2021-02-17 2023-10-10 伊莱利利公司 替西帕肽治疗方法
CN116854805B (zh) * 2023-09-05 2023-12-15 杭州湃肽生化科技有限公司 替尔泊肽的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200119A1 (ar) * 2015-01-09 2017-06-16 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
JP2021533094A (ja) * 2018-07-23 2021-12-02 イーライ リリー アンド カンパニー 療法のためｇｉｐ／ｇｌｐ１コアゴニストを使用する方法
TW202115086A (zh) * 2019-06-28 2021-04-16 美商輝瑞大藥廠 Bckdk抑制劑
WO2022271611A1 (en) * 2021-06-25 2022-12-29 Eli Lilly And Company Methods for treating obstructive sleep apnea

Also Published As

Publication number Publication date
MX2022009384A (es) 2022-11-07
WO2021154593A1 (en) 2021-08-05
AU2021213064A1 (en) 2022-08-25
EP4096703A1 (en) 2022-12-07
KR20220132607A (ko) 2022-09-30
CN115279395A (zh) 2022-11-01
TW202228762A (zh) 2022-08-01
US20230355719A1 (en) 2023-11-09
TW202140058A (zh) 2021-11-01
JP2023513076A (ja) 2023-03-30
EP4096703A4 (en) 2024-02-28
JP2024056786A (ja) 2024-04-23
CA3166567A1 (en) 2021-08-05
IL295181A (en) 2022-09-01

Similar Documents

Publication Publication Date Title
BR112022015015A2 (pt) Usos terapêuticos de tirzepatida
BR112022017393A2 (pt) Composto, composição farmacêutica, método para tratar um transtorno mediado por brd9, e, uso de um composto
BR112015028845A2 (pt) compostos para a modulação da quinase e indicações da mesma
WO2020086726A3 (en) Nerve stimulation for treating migraine and other headache conditions
NZ735000A (en) Methods for the treatment of abnormal involuntary movement disorders
MX2022016415A (es) Inhibidores de glicolato oxidasa para el tratamiento de enfermedades.
ZA202210888B (en) Mtorc1 modulators and uses thereof
MX2022015613A (es) Composiciones de benzofurano beneficiosas para trastornos mentales o mejoramiento mental.
BR112022004699A2 (pt) Vs-6063 em combinação com ch5126766 para o tratamento de câncer
MX2022007436A (es) Inhibidores de la autotaxina y sus usos.
MX2018012655A (es) Compuestos y metodos para tratamiento de afecciones neurologicas y cardiovasculares.
KR20180084610A (ko) 신생아 ｈｉｅ 치료용 조성물
CL2021003045A1 (es) Tratamiento de la disfunción sistólica
CO2021002087A2 (es) Método para tratar la epilepsia
EP4295910A3 (en) Methods for treating multiple sclerosis using pyrimidine and pyridine compounds with btk inhibitory activity
BR112018013247A2 (pt) tratamentos de combinação compreendendo imidazopirazinonas para o tratamento de distúrbios psiquiátricos e/ou cognitivos
WO2018150276A3 (en) The combination of cotinine plus antioxidant for treatment resistant depression and other neuropathological conditions
BR112022012230A2 (pt) Variantes de progranulina
MX2018009189A (es) Compuestos de anillo de siete miembros de pirimidina.
BR112022013554A2 (pt) Métodos para tratar distúrbios do pênfigo
BR112023001957A2 (pt) Composições e métodos para inibir expressão de lpa
MX2021003515A (es) Compuestos polimorficos y usos de los mismos.
NO20082203L (no) Fremgangsmater for a behandle sentralnervesystemforstyrrelser med en lavdosekombinasjon av escitalopram og bupropion
EP4039267A4 (en) COMPOSITION, COMPRISING TMEM176B, OR AN EXPRESSION OR ACTIVITY REGULATOR THEREOF, USED AS AN ACTIVE SUBSTANCE, FOR THE PREVENTION OR TREATMENT OF A DEGENERATIVE BRAIN DISEASE
GB2557471A (en) Arginine silicate inositol for improving cognitive function